Bionano Genomics, INC

Bionano Genomics has appointed former foundational team member Dr. Alex Hastie as its new Chief Scientific Officer, effective July 20, 2026.

Bionano Genomics, Inc. announced that Chief Medical Officer Alka Chaubey, Ph.D. will resign from her position effective July 5, 2026.

Bionano Genomics has fully repaid its $20 million in outstanding senior secured convertible debentures, eliminating all associated liens and restrictive covenants.

Bionano Genomics, Inc. reported on its 2026 Annual Meeting of Stockholders, detailing director elections, executive compensation advisory vote, and ratification of its independent auditor.

Bionano Genomics announced its first quarter 2026 financial results, reporting a 4% increase in total revenue to $6.7 million, driven by a 20% rise in consumables revenue.

Bionano Genomics has appointed Albert A. Luderer, Ph.D. as Interim CEO following the immediate termination of R. Erik Holmlin, Ph.D., effective May 5, 2026.

Bionano Genomics reported a 4% increase in Q1 2026 revenue to $6.7 million, driven by instrument and consumable sales, but continues to face substantial doubt about its ability to continue as a going concern.

Bionano Genomics reported a significant reduction in net loss for Q3 2025, driven by cost-saving initiatives, but acknowledged substantial doubt about its ability to continue as a going concern without further capital.

Bionano Genomics, Inc. reported a reduced net loss for Q2 2025, driven by significant cost-cutting measures, but faces substantial doubt about its ability to continue as a going concern without further capital raises.

Bionano Genomics' Q1 2025 results reveal a revenue decrease due to a strategic shift focusing on existing customers, alongside efforts to manage liquidity and explore strategic alternatives.

Bionano Genomics' Q3 2024 results reflect a strategic shift towards existing customers and cost-cutting measures, impacting revenue and incurring significant impairment charges.

Bionano Genomics' Q2 2024 results show a decrease in revenue and a net loss, alongside significant cost-cutting measures and a strategic review of options.

Bionano Genomics reported a significant reduction in net losses for 2025, driven by cost-saving initiatives, but faces ongoing substantial doubt about its ability to continue as a going concern without further capital.

Bionano Genomics reports a 15% decrease in total revenue for 2024, shifting focus to installed base utilization and cost savings.

Bionano Genomics' 10-K filing highlights the company's focus on optical genome mapping (OGM) technology, commercial expansion, and ongoing financial challenges.

General Counsel Jonathan V. Dixon reported the withholding of 24 shares of Bionano Genomics common stock to satisfy tax obligations.

Bionano Genomics Chief Operating Officer Mark Oldakowski disposed of 27 shares to satisfy tax obligations related to RSU vesting.

Chief Medical Officer Alka Chaubey reported the withholding of 24 shares to satisfy tax obligations related to RSU vesting.

Principal Accounting Officer Mark Adamchak reported the withholding of 7 shares of common stock to satisfy tax obligations related to an RSU award.

Director Aleksandar Rajkovic was granted 9,149 stock options in Bionano Genomics as part of standard equity compensation.

Director Yvonne Linney was granted 9,149 stock options in Bionano Genomics, Inc. as part of equity compensation.

Bionano Genomics has issued its 2026 proxy statement, outlining proposals for director elections, executive compensation, and auditor ratification.

Bionano Genomics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Bionano Genomics is asking stockholders to approve the issuance of shares upon exercise of warrants from a January 2025 securities purchase agreement to comply with Nasdaq listing rules.

Bionano Genomics is urging its stockholders to vote in favor of Proposal 2, a reverse stock split, to maintain its Nasdaq listing and improve its ability to raise capital.

Bionano Genomics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Bionano Genomics is holding a special meeting to seek shareholder approval for the issuance of shares related to warrants and a potential reverse stock split to maintain Nasdaq compliance.

Bionano Genomics, Inc. announces a public offering of up to 2,032,520 shares of common stock, pre-funded warrants, and accompanying Series E and F warrants, aiming to raise approximately $9.0 million in net proceeds for working capital and general corporate purposes, while also disclosing a going concern risk.

CVI Investments and Heights Capital Management have disclosed a 9.9% beneficial ownership stake in Bionano Genomics, primarily through warrants.

Lind Global Fund III LP and its affiliates have reported a 9.9% beneficial ownership stake in Bionano Genomics, Inc., primarily through exercisable warrants.

Iroquois Capital Management, LLC, Richard Abbe, and Kimberly Page have filed an amended Schedule 13G disclosing their beneficial ownership in BriaCell Therapeutics Corp., including warrants subject to a 4.99% ownership blocker.

Iroquois Capital Management, LLC, along with Richard Abbe and Kimberly Page, reported a 4.99% beneficial ownership stake in Bionano Genomics, Inc., including shares from warrants subject to ownership blockers.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Bionano Genomics, Inc., primarily through warrants and a convertible note.

Lind Global Fund III LP and affiliates reported a 9.9% beneficial ownership stake in Bionano Genomics, Inc., comprising common stock and warrants.